Maines Francesca, Caffo Orazio, Donner Davide, Sperduti Isabella, Bria Emilio, Veccia Antonello, Chierichetti Franca, Tortora Giampaolo, Galligioni Enzo
Medical Oncology, S. Chiara Hospital, Largo Medaglie d'oro 1, 38100 Trento, Italy.
Nuclear Medicine, S. Chiara Hospital, Largo Medaglie d'oro 1, 38100 Trento, Italy.
Future Oncol. 2016 Feb;12(3):333-42. doi: 10.2217/fon.15.277. Epub 2016 Jan 15.
High rate of non-target lesions in metastatic castration-resistant prostate cancer usually limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and this has led to a growing interest in using PET/computed tomography (CT). We prospectively investigated the role of (18)F-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel.
PATIENTS & METHODS: 30 patients were monitored by means of FCH-PET/CT before and during the treatment. A Cox proportional hazards regression model was used to assess the associations between metabolic parameters and clinical outcomes.
Univariate analysis showed no significant correlation between biochemical and FCH-PET responses. Multivariate analysis showed that only baseline maximum standardized uptake value (SUVmax) significantly correlated with biochemical progression-free survival, radiological progression-free survival and overall survival.
Our findings suggest that FCH-PET/CT may play a role in defining prognosis of patients receiving enzalutamide because baseline SUVmax proved to be an independent prognostic factor.
转移性去势抵抗性前列腺癌中非靶病变的高发生率通常限制了实体瘤疗效评价标准（RECIST）的适用性，这使得人们对使用正电子发射断层扫描/计算机断层扫描（PET/CT）的兴趣日益增加。我们前瞻性地研究了氟代胆碱（FCH）-PET/CT在多西他赛后接受恩杂鲁胺治疗的患者中的作用。
30例患者在治疗前和治疗期间通过FCH-PET/CT进行监测。采用Cox比例风险回归模型评估代谢参数与临床结局之间的关联。
单因素分析显示生化反应与FCH-PET反应之间无显著相关性。多因素分析显示，仅基线最大标准化摄取值（SUVmax）与生化无进展生存期、影像学无进展生存期和总生存期显著相关。
我们的研究结果表明，FCH-PET/CT可能在确定接受恩杂鲁胺治疗患者的预后中发挥作用，因为基线SUVmax被证明是一个独立的预后因素。
